

Guiding the Future of Drug Development

Resverlogix is a global leader in developing epigenetic therapies to improve the health and well-being of people suffering from chronic illnesses.

By harnessing the ability of epigenetic therapies to correct flawed signals within our cells, we can effectively regulate the expression of disease-causing genes



Apabetalone:

A Thoroughly Characterized, De-risked Asset with a Track Record of Safety and Efficacy



Robust Intellectual Property Protection (to 2040)



FDA Breakthrough Therapy Designation



40+ peer-reviewed publications (incl. **Cell, Nature**)



4200+ patient-years of FDA-reviewed safety data



Detailed **proteomic & transcriptomic** analyses


Apabetalone: Designed to Regulate Gene Expression

Discovered in 2006, and with multiple patent protections until 2040, apabetalone is our lead drug.

Apabetalone is an oral therapy with the ability to normalize the dysregulated epigenetics of multiple chronic diseases and address critical unmet medical need.

Breakthrough Therapy Designation

Apabetalone is the first therapy of its kind to receive breakthrough therapy designation from the US Food and Drug Administration for high-risk cardiovascular disease



Without Altering DNA

Apabetalone regulates expression of disease-causing genes

Epigenetic Mechanism

Through inhibition BET proteins, apabetalone acts at the level of gene transcription

Acting Upstream

Conventional pharmaceuticals target single proteins, while apabetalone can benefit multiple dysregulated pathways

Indication	Phase 1	Phase 2	Phase 3
High-Risk CVD Type 2 Diabetes Mellitus, Low HDL-C, and Recent ACS		ASSERT [2b] SUSTAIN [2b] ASSURE [2b]	BETonMACE (Completed) BETonMACE2 (Ready)
High-Risk CKD Type 2 Diabetes Mellitus, CVD, and CKD			BETonCKD (Ready)
Post COVID-19 Conditions			Phase2/3 (Planned)
PAH	APPRoACH-p (Completed)	APPRoACH-2 (Planned)	
Vascular Dementia			BETonMACE (Subgroup)
Combined Patient-years of Safety			4200

Recent Updates

September 28, 2022

Resverlogix Confirms Focus on Treatment of Post COVID-19 Conditions

August 22, 2022

Resverlogix Publishes New Data Highlighting Apabetalone's Benefit in Non-alcoholic Fatty Liver Disease

August 15, 2022

Resverlogix Announces Appointment of New Chief Scientific Officer

We Thrive on Our Solid Partnerships



Our Management Team



Donald J. McCaffrey

President & Chief Executive Officer
Co-Founder



Dr Ewelina Kulikowski

PhD
Chief Scientific Officer



Dr Michael Sweeney

MD
SVP, Clinical Development



Brad Cann

CPA, CA, CBV
Chief Financial Officer



Dr Jan O. Johansson

MD, PhD
SVP, Medical Affairs



Dr Henrik C. Hansen

PhD
VP, Intellectual Property



Dr Ravi Jahagirdar

DVM, MS
VP, Pharmacology, Toxicology & Safety

Contact Information

ir@resverlogix.com

403 254 9252

Follow Us

@Resverlogix_RVX

[linkedin.com/company/resverlogix-corp/](https://www.linkedin.com/company/resverlogix-corp/)